apd916
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2010 (NCT01093508)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Histamine H3 receptorINVERSE AGONIST
HRH3 inverse agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- apd916
- apd916
- (r)-1-(2-(4'-(3-methoxypropylsulfonyl)biphenyl-4-yl)ethyl)-2-methylpyrrolidine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01093508 | Phase 1 | Mar 1, 2010 | Arena Pharmaceuticals, Community Research, Cincinnati, OH |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Arena Pharmaceuticals | For profit | 1 | 1 | 1 | 2010 |
| Community Research, Cincinnati, OH | For profit | 1 | 0 | 1 | 2010 |
2 organizations
Page 1 / 1